Modeling the public health impact of different meningococcal vaccination strategies with 4CMenB and MenACWY versus the current toddler MenACWY National Immunization Program in Chile

References

• Borrow R, AlarcónP, Carlos J, Caugant DA, ChristensenH, Debbag R, De WalsP, Echániz-Aviles G, Findlow J, Head C, et al. The Global Meningococcal Initiative: global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection. Expert Rev Vaccines. 2017;16:313–28. doi:10.1080/14760584.2017.1258308.
   PubMed Web of Science ®Google Scholar
• Vespa Presa J, Abalos MG, Sini de Almeida R, Cane A. Epidemiological burden of meningococcal disease in Latin America: a systematic literature review. Int J Infect Dis. 2019;85:37–48. doi:10.1016/j.ijid.2019.05.006.
   PubMed Web of Science ®Google Scholar
• Booy R, Gentile A, Nissen M, Whelan J, AbitbolV. Recent changes in the epidemiology of Neisseria meningitidis serogroup W across the world, current vaccination policy choices and possible future strategies. Hum Vaccin Immunother. 2019;15:470–80. doi:10.1080/21645515.2018.1532248.
   PubMed Web of Science ®Google Scholar
• Trotter CL, Gay NJ, EdmundsWJ. The natural history of meningococcal carriage and disease. Epidemiol Infect. 2006;134:556–66. doi:10.1017/s0950268805005339.
   PubMed Web of Science ®Google Scholar
• Christensen H, May M, Bowen L, Hickman M, TrotterCL. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10:853–61. doi:10.1016/s1473-3099(10)70251-6.
   PubMed Web of Science ®Google Scholar
• Viner RM, Booy R, Johnson H, Edmunds WJ, Hudson L, Bedford H, Kaczmarski E, Rajput K, RamsayM, Christie D. Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study. Lancet Neurol. 2012;11:774–83. doi:10.1016/S1474-4422(12)70180-1.
   PubMed Web of Science ®Google Scholar
• Wang B, Clarke M, Thomas N, Howell S, Afzali HH, Marshall H. The clinical burden and predictors of sequelae following invasive meningococcal disease in Australian children. Pediatr Infect Dis J. 2014;33:316–18. doi:10.1097/inf.0000000000000043.
   PubMed Web of Science ®Google Scholar
• Ministerio de Salud. Boletín Epidemiológico Trimestral - Enfermedad Meningocócica, SE 1 – 52. 2019 [accessed 2021 May 6]. http://epi.minsal.cl/wp-content/uploads/2020/01/BET_MENINGITIS_A%C3%91O_-2019.pdf.
   Google Scholar
• Olbrich KJ, Muller D, Schumacher S, Beck E, MeszarosK, Koerber F. Systematic review of invasive meningococcal disease: sequelae and quality of life impact on patients and their caregivers. Infect Dis Ther. 2018;7:421–38. doi:10.1007/s40121-018-0213-2.
   PubMed Web of Science ®Google Scholar
• VillenaR, SafadiMAP, Valenzuela MT, Torres JP, FinnA, O’RyanM. Global epidemiology of serogroup B meningococcal disease and opportunities for prevention with novel recombinant protein vaccines. Hum Vaccin Immunother. 2018;14:1042–57. doi:10.1080/21645515.2018.1458175.
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). WHO position paper on meningococcal vaccines. 2011 [accessed 2021 Apr 19]. https://www.who.int/immunization/position_papers/PP_meningococcal_November_2011_presentation.pdf?ua=1.
   Google Scholar
• SerraLC, York LJ, Gamil A, Balmer P, Webber C. A review of meningococcal disease and vaccination recommendations for travelers. Infect Dis Ther. 2018;7:219–34. doi:10.1007/s40121-018-0196-z.
   PubMed Web of Science ®Google Scholar
• Martinón-Torres F, Safadi MAP, Martinez AC, Marquez PI, Torres JCT, Weckx LY, Moreira EDJ, Mensi I, Calabresi M, Toneatto D. Reduced schedules of 4CMenB vaccine in infants and catch-up series in children: immunogenicity and safety results from a randomised open-label phase 3b trial. Vaccine. 2017;35:3548–57. doi:10.1016/j.vaccine.2017.05.023.
   PubMed Web of Science ®Google Scholar
• GSK. Bexsero - Vacuna Meningocócica Multicomponente del Grupo B. [accessed 2021 May 6]. https://gskpro.com/content/dam/global/hcpportal/es_CL/PDFs/Homepage/products/bexsero/CL_IP_Bexsero.pdf.
   Google Scholar
• Ladhani SN, Campbell H, Andrews N, Parikh SR, White J, Edelstein M, Clark SA, Lucidarme J, Borrow R, Ramsay ME. First real-world evidence of meningococcal group B vaccine, 4CMenB, protection against meningococcal group W disease: prospective enhanced national surveillance, England. Clin Infect Dis. 2020. doi:10.1093/cid/ciaa1244.
   Web of Science ®Google Scholar
• Biolchi A, TomeiS, BrunelliB, GiulianiM, BambiniS, Borrow R, ClausH, GorlaMCO, Hong E, Lemos APS, et al. 4CMenB immunization induces serum bactericidal antibodies against non-serogroup B meningococcal strains in adolescents. Infect Dis Ther. 2021;10:307–16. doi:10.1007/s40121-020-00370-x.
   PubMed Web of Science ®Google Scholar
• Pizza M, Biolchi A, De Angelis G, Moschioni M, Tomei S, Brunelli B, Giuliani M, Bambini S, Borrow R, Claus H, et al. Abstract ESPID19-0255: a multicomponent meningococcal serogroup B vaccine developed for serogroup B meningococci elicits cross-reactive immunity against serogroups C, W and Y. Presented at: European Society for Paediatric Infectious Diseases, 37th Annual Meeting, Ljubljana, Slovenia; 2019.
   Google Scholar
• GSK. US prescribing information: Menveo. 2010 [accessed 2021 Apr 19]. https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Menveo/pdf/MENVEO.PDF.
   Google Scholar
• GSK. Menveo - Vacuna conjugada contra meningococo de los serogrupos A, C, W-135 e Y. 2018 [accessed 2021 May 6]. https://gskpro.com/content/dam/global/hcpportal/es_CL/PDFs/Homepage/products/Menveo/CL_IP_Menveo.pdf.
   Google Scholar
• Read RC, Baxter D, Chadwick DR, Faust SN, Finn A, Gordon SB, Heath PT, Lewis DJ, Pollard AJ, Turner DP, et al. Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial. Lancet (London, England). 2014;384:2123–31. doi:10.1016/s0140-6736(14)60842-4.
   PubMed Web of Science ®Google Scholar
• Moreno G, LópezD, Vergara N, GallegosD, Advis MF, Loayza S. Clinical characterization of cases with meningococcal disease by W135 group in Chile, 2012. Rev Chil Infectol. 2013;30:350–60. doi:10.4067/s0716-10182013000400002.
   PubMed Web of Science ®Google Scholar
• ValenzuelaMT, MorenoG, Vaquero A, Seoane M, HormazábalJC, BertogliaMP, Gallegos D, Sotomayor V, DíazJ. Emergence of W135 meningococcal serogroup in Chile during 2012. Rev Med Chil. 2013;141:959–67. doi:10.4067/s0034-98872013000800001.
   PubMed Web of Science ®Google Scholar
• Villena R, Valenzuela MT, Bastías M, SantolayaME. Meningococcal invasive disease by serogroup W and use of ACWY conjugate vaccines as control strategy in Chile. Vaccine. 2019;37:6915–21. doi:10.1016/j.vaccine.2019.09.050.
   PubMed Web of Science ®Google Scholar
• Díaz J, Cárcamo M, Seoane M, Pidal P, Cavada G, Puentes R, Terrazas S, Araya P, Ibarz-Pavon AB, Manríquez M, et al. Prevalence of meningococcal carriage in children and adolescents aged 10–19 years in Chile in 2013. J Infect Public Health. 2016;9:506–15. doi:10.1016/j.jiph.2015.12.011.
   PubMed Web of Science ®Google Scholar
• Ministerio de Salud. Recomendaciones para la vacunación de pacientes con necesidades especiales por patologías o situaciones de riesgo. 2018 [accessed 2021 Jun 9]. https://vacunas.minsal.cl/wp-content/uploads/2020/02/Recomendaciones-para-la-vacunaci%C3%B3n-de-pacientes-con-necesidades-especiales.pdf.
   Google Scholar
• Ministerio de Salud. Ord-B27-N°-4293-Informa incorporacion de la vacuna antimeningococica del grupo B. 2019 [accessed 2021 Jun 9]. https://vacunas.minsal.cl/wp-content/uploads/2020/07/Ord-B27-N%C2%B0-4293-Informa-incorporacion-de-la-vacuna-antimeningococica-del-grupo-B-del-Lab.-Glaxosmithkline-23-sept-2019.pdf.
   Google Scholar
• BeckE, KlintJ, GarciaS, Abbing V, Abitbol V, Akerborg O, Argante L, Bekkat-Berkani R, Hogea C, NeineM, et al. Modelling the impact of 4CMenB and MenACWY meningococcal combined vaccination strategies including potential 4CMenB cross-protection: an application to England. Vaccine. 2020;38:7558–68. doi:10.1016/j.vaccine.2020.08.007.
   PubMed Web of Science ®Google Scholar
• Beck E, Klint J, Neine M, Garcia S, Meszaros K. Cost-effectiveness of 4CMenB infant vaccination in England: a comprehensive valuation considering the broad impact of serogroup B invasive meningococcal disease. Value Health. 2021;24:91–104. doi:10.1016/j.jval.2020.09.004.
   PubMed Web of Science ®Google Scholar
• El Instituto Nacional de Estadísticas. Censo 2017. 2017 [accessed 2020 Jul 7]. https://www.censo2017.cl/.
   Google Scholar
• Valenzuela MT, Mañalich J, Díaz J, Linazasoro I, Castillo L, Morales AM, Villena R. National action plan for the emergence of invasive meningococcal disease in Chile, 2012–2013. Rev Med Chil. 2019;147:776–86. doi:10.4067/s0034-98872019000600776.
   PubMed Web of Science ®Google Scholar
• Health statistics Department Chile. Nacimientos. 2020 [accessed 2021 Jun 9]. https://deis.minsal.cl/#estadisticas.
   Google Scholar
• Health Statistics Department Chile. Defunciones y Mortalidad General. 2020 [accessed 2021 Jun 9]. https://deis.minsal.cl/#estadisticas.
   Google Scholar
• Gobierno de Chile. Solicitud de Información Ley de Transparencia. 2008 [accessed 2021 Jun 9]. http://transparencia.redsalud.gov.cl/transparencia/public/isp/solicitud_informacion.html.
   Google Scholar
• Health statistics Department Chile. Hospital discharge database 2012–2018 - Egresos hospitalarios. 2020 [accessed 2021 Jun 9]. https://deis.minsal.cl/#estadisticas.
   Google Scholar
• Bettinger JA, Scheifele DW, Le Saux N, Halperin SA, Vaudry W, Tsang R. For the members of Canadian immunization monitoring program AI. The disease burden of invasive meningococcal serogroup B disease in Canada. Pediatr Infect Dis J. 2013;32:e20–e25. doi:10.1097/INF.0b013e3182706b89.
   PubMed Web of Science ®Google Scholar
• Rodriguez P, Alvarez I, Torres MT, Diaz J, Bertoglia MP, Carcamo M, Seoane M, Araya P, Russo M, Santolaya ME. Meningococcal carriage prevalence in university students, 1824 years of age in Santiago, Chile. Vaccine. 2014;32:5677–80. doi:10.1016/j.vaccine.2014.08.015.
   PubMed Web of Science ®Google Scholar
• Soeters HM, Whaley M, Alexander-Scott N, Kanadanian KV, MacNeilJR, Martin SW, McNamara LA, Sicard K, Vanner C, Vuong J, et al. Meningococcal carriage evaluation in response to a serogroup B meningococcal disease outbreak and mass vaccination campaign at a College-Rhode Island, 2015–2016. Clin Infect Dis. 2017;64:1115–22. doi:10.1093/cid/cix091.
   PubMed Web of Science ®Google Scholar
• Departamento de Estadísticas e Información de Salud. Cobertura de vacunación programática Infantil 2019–2020. 2019 [accessed 2020 Aug 19]. https://deis.minsal.cl/.
   Google Scholar
• Rubilar PS, Barra GN, Gabastou JM, Alarcón P, Araya P, Hormazábal JC, Fernandez J. Increase of Neisseria meningitidis W: cc11 invasive disease in Chile has no correlation with carriage in adolescents. PloS One. 2018;13:e0193572. doi:10.1371/journal.pone.0193572.
   PubMed Web of Science ®Google Scholar
• Rodrigues F. Portuguese meningococcus group B vaccine effectiveness study (PT-BEST) - preliminary results. Presented at: 15th European Meningococcal and Haemophilus Disease Society (EMGM) Congress; 2019; Lisbon, Portugal.
   Google Scholar
• Cohn AC, MacNeil JR, Harrison LH, Lynfield R, Reingold A, Schaffner W, Zell ER, Plikaytis B, WangX, Messonnier NE. Effectiveness and duration of protection of one dose of a meningococcal conjugate vaccine. Pediatrics. 2017:139. doi:10.1542/peds.2016-2193.
   Web of Science ®Google Scholar
• Martinon-Torres F, Carmona Martinez A, Simko R, Infante Marquez P, Arimany JL, Gimenez-Sanchez F, Couceiro Gianzo JA, Kovacs E, Rojo P, Wang H, et al. Antibody persistence and booster responses 24–36 months after different 4CMenB vaccination schedules in infants and children: a randomised trial. J Infect. 2018;76:258–69. doi:10.1016/j.jinf.2017.12.005.
   PubMed Web of Science ®Google Scholar
• VesikariT, ForstenA, BiancoV, Van der WielenM, MillerJM. Immunogenicity, safety and antibody persistence of a booster dose of quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine compared with monovalent meningococcal serogroup C vaccine administered four years after primary vaccination using the same vaccines. Pediatr Infect Dis J. 2015;34:e298–307. doi:10.1097/inf.0000000000000897.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Forsten A, Bianco V, Van der Wielen M, Miller JM. Antibody persistence up to 5 years after vaccination of toddlers and children between 12 months and 10 years of age with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine. Hum Vaccin Immunother. 2016;12:132–39. doi:10.1080/21645515.2015.1058457.
   PubMed Web of Science ®Google Scholar
• Baxter R, Reisinger K, Block SL, Percell S, Odrljin T, Dull PM, Smolenov I. Antibody persistence after primary and booster doses of a quadrivalent meningococcal conjugate vaccine in adolescents. Pediatr Infect Dis J. 2014;33:1169–76. doi:10.1097/inf.0000000000000438.
   PubMed Web of Science ®Google Scholar
• Vickers DM, Anonychuk AM, De Wals P, Demarteau N, Bauch CT. Evaluation of serogroup C and ACWY meningococcal vaccine programs: projected impact on disease burden according to a stochastic two-strain dynamic model. Vaccine. 2015;33:268–75. doi:10.1016/j.vaccine.2013.09.034.
   PubMed Web of Science ®Google Scholar
• Serra L, Presa J, Christensen H, Trotter C. Carriage of Neisseria meningitidis in low and middle income countries of the Americas and Asia: a review of the literature. Infect Dis Ther. 2020;9:209–40. doi:10.1007/s40121-020-00291-9.
   PubMed Web of Science ®Google Scholar
• Nunes AM, Ribeiro GS, Ferreira ÍE, Moura AR, Felzemburgh RD, de Lemos AP, Reis MG, de Moraes JC, Campos LC. Meningococcal carriage among adolescents after mass meningococcal C conjugate vaccination campaigns in Salvador, Brazil. PloS One. 2016;11:e0166475. doi:10.1371/journal.pone.0166475.
   PubMed Web of Science ®Google Scholar
• Sáfadi MAP, Valenzuela MT, Carvalho AF, De Oliveira LH, Salisbury DM, Andrus JK. Knowing the scope of meningococcal disease in Latin America. Rev Panam Salud Publ. 2017;41:e118. doi:10.26633/rpsp.2017.118.
   PubMed Web of Science ®Google Scholar
• Sáfadi MA, O’Ryan M, Valenzuela Bravo MT, Brandileone MC, Gorla MC, de Lemos AP, Moreno G, Vazquez JA, López EL, Taha MK, et al. The current situation of meningococcal disease in Latin America and updated Global Meningococcal Initiative (GMI) recommendations. Vaccine. 2015;33:6529–36. doi:10.1016/j.vaccine.2015.10.055.
   PubMed Web of Science ®Google Scholar